arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AMGEN INC

AMGN
$406.15 ▼ -4.11 (-1.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
75 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

AMGEN INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $219.3B
Dividend Yield 0.62%
Revenue Growth 9.5% ↗
Op. Margin 35.0% ↗
ROIC 4.4% ↗
FCF / Share $6.46 ↗
Trailing P/E 92.3x
Price / Book 18.8x
FCF Yield 1.6%
Debt / Equity 4.90
info Valuation on last close. End-of-day price, Sep 23, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.05B
↑ +9.5% —
Net Income Profit after all expenses
$2.38B
↑ +65.9% —
Operating Margin Operating profit as % of sales
35.0%
↑ +13.0% 81th
FCF / Share Free cash flow per share
$6.46
↑ +136.2% —
Long-Term Debt Long-term obligations
$57.30B
— 0.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
83
Returns →
99
Financial Health →
35
Cash Quality ↓
68

Dividend History

Dividend / share · sourced from SEC filings
$9.66 Latest / share
+5.8% YoY
+28.5% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 75 quarters